Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133591) titled 'Efficacy and Safety of Trastuzumab rezetecan(SHR-A1811) in HER2-Abnormal Solid Tumors: A National Multi-Center Real-World Study' on Sept. 29.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences
Condition:
Histologically/cytologically confirmed advanced/metastatic solid tumor
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-09-30
Target Sample Size: Trastuzumab Rezetecan Treatment Group:2000;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=345752
Publ...